Sleeve Gastrectomy: In this step, approximately 80% of the stomach is removed, reducing its capacity, and decreasing the amount of food a patient can consume. This also reduces the production of the hunger hormone, ghrelin.

Duodenal-Ileal Bypass: In this second step, the remaining end of the stomach is connected directly to the lower small intestine, bypassing a significant portion of the small intestine, approximately 2.3 meters, and consequently reducing calorie and nutrient absorption.

• SADI-S is a highly effective as a revisional procedure after failed sleeve gastrectomy, and may be an option after other failed bariatric procedures: banding, Vertical Banded Gastroplasty (VBG), or RYGB

In essence, SADI-s is a hypo absorptive technique that originates from the biliopancreatic diversion, aligning with its fundamental principles. It stands as a standalone surgical procedure for morbidly obese patients and presents a viable option, particularly as an initial step for super-obese patients or those deemed high-risk.

Amount of weight that can be lost:

The amount of weight a patient can lose with SADI-S surgery varies from patient to patient and depends on factors such as the patient's initial weight, adherence to dietary and exercise recommendations, and other individual medical factors. In general, patients have been observed to lose between 60% and 90% of their excess weight within the first year after surgery. demonstrating a comparable weight loss to Gastric Bypass (RYGB) in the mid-term, but showing even superior results in the long-term

1. Pylorus Preservation: This surgery preserves the pylorus, preventing alkaline reflux.
2. Avoidance of Mesentery Opening: It avoids opening the mesentery, reducing the risk of internal hernias.
3. Significant Weight Loss: The reduction in stomach size and modification of the small intestine help control appetite and reduce food intake. This surgery leads to substantial weight loss, exceeding 85% of excess weight within one year of the surgery.
4. Improvement in Medical Conditions: Normalization of glycosylated hemoglobin levels three months after surgery, as well as improvements or remission of obesity-related medical conditions such as type 2 diabetes, hypertension, and sleep apnea.